| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-13 11:48:01 UTC |
|---|
| Update Date | 2022-03-07 02:57:13 UTC |
|---|
| HMDB ID | HMDB0041920 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Loxoprofen |
|---|
| Description | As most NSAIDs, loxoprofen is a non-selective cyclooxygenase inhibitor, and works by reducing the synthesis of prostaglandins from arachidonic acid. Loxoprofen (INN) is a non-steroidal anti-inflammatory drug in the propionic acid derivatives group, which also includes ibuprofen and naproxen among others. It is marketed in Brazil, Mexico and Japan by Sankyo as its sodium salt, loxoprofen sodium, under the trade name Loxonin, Argentina as Oxeno and in India as Loxomac. It is available in these countries for oral administration, and a transdermal preparation was approved for sale in Japan on January 2006. Loxoprofen is a prodrug. It is quickly converted to its active trans-alcohol metabolite following oral administration, and reaches its peak plasma concentration within 30 to 50 minutes. |
|---|
| Structure | CC(C(O)=O)C1=CC=C(CC2CCCC2=O)C=C1 InChI=1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18) |
|---|
| Synonyms | | Value | Source |
|---|
| (+-)-((2-Oxocyclopentyl)methyl)hydratropic acid | ChEBI | | Loxoprofene | ChEBI | | Loxoprofeno | ChEBI | | Loxoprofenum | ChEBI | | (+-)-((2-Oxocyclopentyl)methyl)hydratropate | Generator | | Loxoprofen sodium hydrate | HMDB | | Loxoprofen alcohol | HMDB | | Sodium 2-(4-(2-oxocyclopentylmethyl)phenyl)propionate dihydrate | HMDB | | Loxoprofen sodium, (r*,s*)-isomer | HMDB | | 2-(4-((2-Oxocyclopentyl)methyl)phenyl)propionic acid | HMDB | | 2-OCPPP | HMDB | | Loxoprofen sodium dihydrate | HMDB | | Sodium loxoprofen | HMDB |
|
|---|
| Chemical Formula | C15H18O3 |
|---|
| Average Molecular Weight | 246.3016 |
|---|
| Monoisotopic Molecular Weight | 246.125594442 |
|---|
| IUPAC Name | 2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid |
|---|
| Traditional Name | loxoprofen |
|---|
| CAS Registry Number | 80382-23-6 |
|---|
| SMILES | CC(C(O)=O)C1=CC=C(CC2CCCC2=O)C=C1 |
|---|
| InChI Identifier | InChI=1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18) |
|---|
| InChI Key | YMBXTVYHTMGZDW-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as phenylpropanoic acids. Phenylpropanoic acids are compounds with a structure containing a benzene ring conjugated to a propanoic acid. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Phenylpropanoids and polyketides |
|---|
| Class | Phenylpropanoic acids |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Phenylpropanoic acids |
|---|
| Alternative Parents | |
|---|
| Substituents | - 2-phenylpropanoic-acid
- P-cymene
- Aromatic monoterpenoid
- Monocyclic monoterpenoid
- Monoterpenoid
- Monocyclic benzene moiety
- Benzenoid
- Ketone
- Cyclic ketone
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Carboxylic acid derivative
- Carbonyl group
- Hydrocarbon derivative
- Organic oxide
- Organic oxygen compound
- Organooxygen compound
- Aromatic homomonocyclic compound
|
|---|
| Molecular Framework | Aromatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 6.45 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 13.5172 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.33 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 28.0 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2180.1 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 374.4 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 172.5 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 198.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 223.0 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 555.0 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 566.9 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 78.5 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1226.4 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 480.2 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1294.5 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 320.9 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 383.5 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 288.0 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 258.5 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 30.8 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Loxoprofen,1TMS,isomer #1 | CC(C(=O)O[Si](C)(C)C)C1=CC=C(CC2CCCC2=O)C=C1 | 2173.9 | Semi standard non polar | 33892256 | | Loxoprofen,1TMS,isomer #2 | CC(C(=O)O)C1=CC=C(CC2=C(O[Si](C)(C)C)CCC2)C=C1 | 2256.6 | Semi standard non polar | 33892256 | | Loxoprofen,1TMS,isomer #3 | CC(C(=O)O)C1=CC=C(CC2CCC=C2O[Si](C)(C)C)C=C1 | 2220.9 | Semi standard non polar | 33892256 | | Loxoprofen,2TMS,isomer #1 | CC(C(=O)O[Si](C)(C)C)C1=CC=C(CC2=C(O[Si](C)(C)C)CCC2)C=C1 | 2255.0 | Semi standard non polar | 33892256 | | Loxoprofen,2TMS,isomer #1 | CC(C(=O)O[Si](C)(C)C)C1=CC=C(CC2=C(O[Si](C)(C)C)CCC2)C=C1 | 2187.0 | Standard non polar | 33892256 | | Loxoprofen,2TMS,isomer #2 | CC(C(=O)O[Si](C)(C)C)C1=CC=C(CC2CCC=C2O[Si](C)(C)C)C=C1 | 2208.1 | Semi standard non polar | 33892256 | | Loxoprofen,2TMS,isomer #2 | CC(C(=O)O[Si](C)(C)C)C1=CC=C(CC2CCC=C2O[Si](C)(C)C)C=C1 | 2147.3 | Standard non polar | 33892256 | | Loxoprofen,1TBDMS,isomer #1 | CC(C(=O)O[Si](C)(C)C(C)(C)C)C1=CC=C(CC2CCCC2=O)C=C1 | 2438.1 | Semi standard non polar | 33892256 | | Loxoprofen,1TBDMS,isomer #2 | CC(C(=O)O)C1=CC=C(CC2=C(O[Si](C)(C)C(C)(C)C)CCC2)C=C1 | 2555.1 | Semi standard non polar | 33892256 | | Loxoprofen,1TBDMS,isomer #3 | CC(C(=O)O)C1=CC=C(CC2CCC=C2O[Si](C)(C)C(C)(C)C)C=C1 | 2494.5 | Semi standard non polar | 33892256 | | Loxoprofen,2TBDMS,isomer #1 | CC(C(=O)O[Si](C)(C)C(C)(C)C)C1=CC=C(CC2=C(O[Si](C)(C)C(C)(C)C)CCC2)C=C1 | 2763.0 | Semi standard non polar | 33892256 | | Loxoprofen,2TBDMS,isomer #1 | CC(C(=O)O[Si](C)(C)C(C)(C)C)C1=CC=C(CC2=C(O[Si](C)(C)C(C)(C)C)CCC2)C=C1 | 2617.1 | Standard non polar | 33892256 | | Loxoprofen,2TBDMS,isomer #2 | CC(C(=O)O[Si](C)(C)C(C)(C)C)C1=CC=C(CC2CCC=C2O[Si](C)(C)C(C)(C)C)C=C1 | 2698.0 | Semi standard non polar | 33892256 | | Loxoprofen,2TBDMS,isomer #2 | CC(C(=O)O[Si](C)(C)C(C)(C)C)C1=CC=C(CC2CCC=C2O[Si](C)(C)C(C)(C)C)C=C1 | 2509.2 | Standard non polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Loxoprofen GC-MS (Non-derivatized) - 70eV, Positive | splash10-0gi0-2950000000-f1f143e2589e1aea4173 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Loxoprofen GC-MS (1 TMS) - 70eV, Positive | splash10-0600-9882000000-95383cbac1177e9a0726 | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Loxoprofen GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Loxoprofen GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Loxoprofen 35V, Positive-QTOF | splash10-0zfr-0890000000-74ee0167cd6a76ef67d0 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Loxoprofen 35V, Negative-QTOF | splash10-001i-0090000000-1b731099acfc2cee4d1a | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Loxoprofen 10V, Positive-QTOF | splash10-0002-1290000000-9a370ea3c1893f34ac6a | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Loxoprofen 20V, Positive-QTOF | splash10-0umj-3940000000-2a5656d17e3cdb5b29ac | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Loxoprofen 40V, Positive-QTOF | splash10-0kx0-1900000000-f6a4fd9d3ed427851cb0 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Loxoprofen 10V, Negative-QTOF | splash10-0002-0090000000-c0fa095368edf3656575 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Loxoprofen 20V, Negative-QTOF | splash10-0udj-2290000000-a000dad805df140f2aeb | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Loxoprofen 40V, Negative-QTOF | splash10-00ai-9200000000-485777b0ba108a03a92f | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Loxoprofen 10V, Negative-QTOF | splash10-0f6t-0190000000-319eb623e74a18ded3a7 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Loxoprofen 20V, Negative-QTOF | splash10-0udi-0390000000-0d1645d8c8daa3d6be44 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Loxoprofen 40V, Negative-QTOF | splash10-014i-2900000000-8d006d601c3437f0eb2f | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Loxoprofen 10V, Positive-QTOF | splash10-01u0-0690000000-117230d5ff547c24425e | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Loxoprofen 20V, Positive-QTOF | splash10-02bb-2940000000-c41c0ae60ad2bd310b62 | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Loxoprofen 40V, Positive-QTOF | splash10-0159-2900000000-457bd9b0f844b6308beb | 2021-09-25 | Wishart Lab | View Spectrum |
|
|---|